Although mutations in the subunit of AMP-activated protein kinase (AMPK) result in excessive glycogen accumulation and cardiac hypertrophy, the mechanisms by which this occurs have not been well defined. As greater than 65% of cardiac AMPK activity is associated with the 1 subunit of AMPK, we investigated the effects of expression of an AMPK-activating 1 subunit mutant ( 1 R70Q) on regulatory pathways controlling glycogen accumulation and cardiac hypertrophy in neonatal rat cardiac myocytes.
INTRODUCTION
AMPK is a heterotrimeric serine/threonine kinase consisting of a catalytic subunit and regulatory and subunits. Of these two regulatory subunits, the subunit is thought to 'sense' the cellular energy state by virtue of its ability to bind ATP and AMP (10) . In most mammalian cell types, AMPK is activated as a means to maintain adequate ATP levels during times of metabolic stress (22) . In the heart, activation of AMPK by ischemia is associated with increased glucose uptake (37) , and stimulation of ATP production via both increased glycolysis (33) and fatty acid oxidation (38) . In addition, AMPK activation has been suggested to be involved in the regulation of muscle glycogen levels (5) . However, the effects of AMPK activation on the pathways regulating myocardial glycogen levels are controversial. For example, in the stressed heart, AMPK activation has been shown to partition glucose away from glycogen synthesis in favor of glycolysis (24) . In contrast, absence of the AMPK 2 subunit resulted in reduced myocardial glycogen storage (44) . Consistent with AMPK playing a central role in glycogen metabolism, activating mutations in one of the isoforms of the subunit of AMPK found in the heart ( 2 N488I), results in a dramatic increase in cardiac glycogen levels (2, 3) indicating that AMPK activation either promotes glycogen synthesis or inhibits glycogenolysis. Interestingly, a separate mutation in the 2 subunit ( 2 R302Q) also promotes glycogen accumulation in the heart yet this mutation has been reported to be an inactivating mutation of AMPK (12, 40) . Therefore, while the role of AMPK in the regulation of myocardial glucose uptake, glycolysis, and fatty acid oxidation appears to be well established, the mechanism by which AMPK activation controls myocardial glycogen levels has yet to be clearly defined.
Since the subunits of AMPK are important regulators of AMPK activity, considerable research effort has focused on characterizing these subunits. To date, three isoforms of the AMPK subunit have
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Copyright Information 3 been identified, each with its own expression profile (10) . The 1 subunit is ubiquitously expressed, while 2 is found at high levels in both the heart and the brain and 3 is expressed almost exclusively in the skeletal muscle (10) . All subunits contain 2 tandem Bateman domains that are sites of allosteric regulation by adenosine-containing nucleotides (7, 39) . Studies involving the mutations within the Bateman domains of the subunits have shown that the mutations alter either the basal activation of AMPK and/or the response of AMPK to AMP or ATP (20, 39, 45) . These mutations are thought to mimic the allosteric activation of AMP and may make the AMPK holoenzyme a better substrate for upstream kinases such as LKB1, leading to increased phosphorylation of AMPK and activation of the enzyme (45) . One of the better-understood mutations within the CBS domain of the subunit is the 1 R70Q mutation, which results in increased basal AMPK activity in a number of cell types (20) as well as in intact skeletal muscle (6) . As such, expression of the 1 R70Q mutation may provide an alternative genetic means to activate AMPK in the cardiac myocyte as well as potentially providing insight into the effects of mutations on the cellular function of AMPK.
Utilizing the 1 R70Q mutation as a mechanism to activate AMPK in the cardiac myocyte has several advantages over the more commonly used methods such as the non-specific AMPK agonists, or the constitutively active truncated/mutated form of AMPK (31) , which in our hands does not activate AMPK in the neonatal rat cardiac myocyte as it does in other cell types such as the hepatocyte ((23) and unpublished data). In addition, using the 1 R70Q mutation to genetically activate AMPK may also provide insights into how mutations in the subunits cause a cardiomyopathy characterized by: 1) ventricular pre-excitation and 2) hypertrophy and excessive glycogen accumulation (2, 8, 18) . Currently, the mechanisms that promote the latter of these cardiac abnormalities in patients with 2 mutations are not well understood, although some contributing pathways have recently been identified (32) . However, transgenic mouse models of 2 subunit mutations recapitulate the human condition, indicating that this is not a polygenic phenotype, but the result of a single mutation (3, 40) . Despite the obvious importance of
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As such, it is possible that expression of a 1 mutant may induce a more dramatic phenotype than that observed in the 2 mutant-expressing mice. While a transgenic mouse model of the 1 R70Q mutation has been developed, the cDNA for the 1 R70Q mutation is driven by the skeletal muscle -actin promoter, resulting in only very low-level expression in the hearts of these animals (6) . Thus, it is not surprising that these mice do not display cardiac glycogen accumulation (6) or myocardial hypertrophy (unpublished data). What effect, if any, higher level of expression of the 1 R70Q mutation in cardiac myocytes has on AMPK activity, cardiac energy metabolism, glycogen accumulation or cardiac hypertrophy is currently unknown.
Therefore, the aims of this study were to: 1) characterize the metabolic effects of expression of the AMPK-activating 1 R70Q mutation in cardiac myocytes, 2) determine if expression of the 1 R70Q mutation in cardiac myocytes recapitulates aspects of the phenotype observed with expression of the 2 mutations, and 3) identify early molecular signaling events that may contribute to mutation-induced glycogen accumulation and/or cardiac hypertrophy. As glycogen accumulation and/or cardiac hypertrophy occur in hearts expressing mutated versions of the subunit, activation of AMPK via expression of the 1 R70Q mutation should provide valuable insight into the mechanisms involved in regulating the metabolic pathways and signaling events that contribute to development of the cardiac phenotype observed in patients with these mutations.
EXPERIMENTAL PROCEDURES
Animal Care-The University of Alberta complies with National Institutes of Health animal care guidelines and adheres to the principles for biomedical research involving animals developed by the Council for International Organizations of Medical Sciences.
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Cell Culture-Cardiac myocytes were isolated from 1-3 day-old neonatal rat hearts and plated at a density of 2.0x10 6 cells/plate as previously described (26) . Sciences, Inc) pre-bound to 3% fatty acid-free BSA (Sigma) for 3 h. After 48 h of infection at 37 °C in 5% CO2, cells were harvested as described in the appropriate protocol below.
Cell Treatment-After
Measurement of metabolic rates-
Following treatment with radiolabelled substrate, an aliquot of the cell media was removed and the vapor transfer method was utilized to determine metabolic rates essentially as previously described (16) . Following sampling of the media, cells were scraped and lysed as described by 6 Kovacic et al (26) . The protein concentration of the supernatant was then determined with the Bradford protein assay (Bio-Rad) and radioactivity counts were standardized to protein content.
Measurement of AMPK activity-The AMPK 1 isoform was immunoprecipitated from 100 µg of protein from cell homogenates with anti-1 antibody (Kinasource) and subjected to an AMPK peptide substrate activity assay as described previously (27).
Measurement of NFAT activity-Cells were lysed and luminescence was detected using the Luciferase Assay System (Promega) according to manufacturer's instructions. Luminescence counts were standardized to protein content. Immunoblot analysis-Cells were harvested and protein concentration determined as described in the metabolic rate assay section. Boiled cell homogenate samples were subjected to SDS-PAGE in 5%, 8%
Measurement of glycogen content and glycogen synthesis rates-Cells
or 10% acrylamide gels and transferred onto nitrocellulose as previously described (41) . Membranes were blocked in 5% milk/1x TBS/0.1% Tween 20 and then immunoblotted at 1:1000 dilution (unless otherwise specified) with either rabbit anti-phospho-AMPK (Thr-172), rabbit anti-AMPK , rabbit
anti-GSK-3 , rabbit anti-phospho-glycogen synthase (Ser-641/645), rabbit anti-glycogen synthase, goat anti-actin, rabbit anti-phospho-acetyl CoA carboxylase (Ser-79) antibody, or peroxidase-labeled 
RESULTS
Expression of 1 R70Q activates AMPK and increases palmitate oxidation rates in neonatal rat cardiac
myocytes -Using our model system we show that expression of 1 R70Q in the cardiac myocyte leads to a 2-fold increase (p<0.01) in phosphorylation of AMPK on threonine 172 (Thr172), compared to the wildtype 1 subunit ( Figure 1A ). Since phosphorylation of Thr172 has been associated with activation of the AMPK, we immunoprecipitated the 1 subunit and measured the associated AMPK activity.
Consistent with the increased phosphorylation of AMPK at Thr172, AMPK activity was significantly increased in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (p<0.05, Figure   1B ).
In order to confirm the intracellular activation of AMPK, the phosphorylation status of both isoforms of acetyl-CoA carboxylase (ACC: ACC , ACC ), were examined. As expected with activation of AMPK, phosphorylation of both the ACC isoforms was increased by more than 2-fold (p<0.01) in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit ( Figure 1C ). In accordance with phosphorylation and inhibition of ACC, there was nearly a doubling of palmitate oxidation rates in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (Figure 2A ; p<0.001). This 9 increase in palmitate oxidation was comparable to that seen with the AMPK activator AICAR (1.89 fold and 1.96 fold increase vs. adenoviral control for Ad 1R70Q and AICAR, respectively).
Expression of 1 R70Q modulates glucose handling in neonatal rat cardiac myocytes-In contrast to the predicted effects of increased AMPK activity on glycolysis, glycolytic rates were dramatically decreased in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (p<0.001, Figure 2B ). In addition, there was more than a 2-fold increase in both the rates of glycogen synthesis and total glycogen content in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (p<0.05 and p<0.005, Figure 2C and 2D, respectively). Consistent with this elevated level of glycogen, there was a significant increase in glycogen synthase activity (p<0.05, Figure 3A ), a reduction in the ratio of inhibitory phosphorylation of glycogen synthase at serine residues 641/645 to total glycogen synthase protein (p<0.05, Figure 3B ), along with elevated levels of glycogen synthase protein (p<0.05, Figure 3B) in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit. Based on the increase in glycogen synthase protein levels, we measured glycogen synthase transcript levels and found that muscle glycogen synthase (gys1) levels were increased by nearly 2.5-fold in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (p<0.01, Figure 3C ). However, unlike the upregulation of the liver isoform of glycogen synthase (gys2) observed in the muscle-specific 1 R70Q transgenic model (6), we found no change in the transcript level of gys2 in cardiac myocytes expressing the 1 R70Q mutation (data not shown).
Expression of 1 R70Q decreases GSK-3 expression and induces NFAT translocation to the nucleus
in neonatal rat cardiac myocytes-As the ratio of phosphorylated to total glycogen synthase was decreased in cells expressing the 1 R70Q mutation, we investigated the kinase responsible for phosphorylation at these sites, glycogen synthase kinase-3 (GSK-3 ). Since phosphorylation of GSK-3 at serine 9 is inversely correlated with its activity, we examined the phosphorylation of GSK-3 at this However, GSK-3 protein levels were decreased by more than 50% in cells expressing the 1 R70Q subunit mutation compared to the wildtype 1 subunit (p<0.01, Figure 4A ). This appears to be specific to the mutation as activation of AMPK in neonatal rat cardiac myocytes via either treatment with phenformin or expression of the LKB1/MO25/STRAD complex does not significantly alter GSK-3 protein levels from control cells (phenformin treatment: 1.19 ± 0.55-fold increase (n=3); LKB1/MO25/STRAD treatment: 1.14 ± 0.39-fold increase (n=3)). The reduction in GSK-3 protein in cells expressing the 1 R70Q subunit mutation was likely due to decreased mRNA levels, as gsk-3 transcript content was also reduced by nearly 50% in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (p<0.01, Figure 4B ).
While GSK-3 plays a major role in the regulation of glycogen synthesis, it also regulates cardiac hypertrophic growth by phosphorylating the transcription factor NFAT, thereby preventing NFAT activation of the hypertrophic gene program (1, 21) . Due to this role of GSK-3 , we determined if expression of the 1 R70Q mutation had an effect on NFAT signaling. To do this, we utilized an adenovirus expressing the luciferase reporter gene under transcriptional control of an NFAT-responsive promoter (43). As adenoviral DNA must be delivered to the nucleus in order to access the transcriptional machinery, only nuclear NFAT can induce transcription of luciferase mRNA, leading to the eventual production of luciferase protein. As predicted by the down-regulation of GSK-3 , activity of the NFATdriven reporter construct was significantly increased in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit (p<0.05, Figure 4C ). Although there was no observable change in cell size at 48 hours of expression in any of the groups, this is not surprising given that expression of the 1 R70Q mutation is likely a very subtle hypertrophic stimuli compared to phenylephrine treatment. However, although not significantly different, protein synthesis rates were increased 1.31 ± 0.25 fold compared to
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DISCUSSION
In order to examine the early signaling events involved in regulating glycogen accumulation and cardiac hypertrophic growth induced by the mutations, we acutely expressed the 1 R70Q mutation in the neonatal rat cardiac myocyte. We chose to express this mutant subunit for a number of reasons: 1) the AMPK complexes containing the 1 subunit account for >65% of the AMPK activity in the heart (30),
suggesting an important role for the 1 subunit in the cardiac myocyte, 2) the 1 R70Q mutation provided us with a genetic means to activate AMPK, and 3) the 1 R70Q mutation is homologous to the 2 R302Q mutation, and as such may potentially provide insight into the general effects of mutations on the intramyocellular function of AMPK. In addition, expressing this mutant in the neonatal rat cardiac myocyte is particularly relevant given that many of the mutations induce symptoms in mice and humans at a very young age (reviewed in (4)). Moreover, acute expression of the 1 R70Q mutation allows us to study the early signaling events of the mutation on AMPK activity in the absence of dramatic glycogen accumulation and/or hypertrophy that are present in the transgenic mice.
Consistent with previous studies in different cell types and in skeletal muscle (6, 20) , we show that expression of 1 R70Q in the cardiac myocyte results in AMPK activation. Indeed, expression of 1 R70Q leads to a 2-fold increase in phosphorylation of AMPK Thr172, with no change in subunit protein levels (data not shown) and a significant increase in 1 subunit-associated AMPK activity, compared to the wildtype 1 subunit ( Figure 1A, 1B) . As a confirmation of the intracellular activation of AMPK, the phosphorylation status of both ACC and ACC (downstream targets of activated AMPK in the heart (13)), was increased by more than 2-fold in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit ( Figure 1C ). As inhibition of ACC generally results in increased rates of fatty acid oxidation (38), we measured the rate of palmitate oxidation in the cardiac myocyte. Cells expressing the 1 R70Q mutation had nearly twice the palmitate oxidation rates compared to the wildtype 1 subunit (Figure 2A ). This increase in palmitate oxidation was similar to that of the AMPK activator AICAR and further supports the view that the 1 R70Q mutation results in activation of AMPK in the cardiac myocyte.
Since AMPK activation has also been shown to have dramatic effects on glucose handling (33, 36) , we further characterized the effects of this mutation on glucose metabolism. In contrast to classical AMPK activation by pharmacological activators or ischemia/hypoxia (33, 34) , AMPK activation induced by the 1 R70Q mutation did not activate glycolysis. In fact, glycolytic rates were drastically reduced in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit ( Figure 2B ) suggesting that the effect is specific to the mutation-mediated increase in AMPK activity. As glucose has two major fates in the cardiac myocyte (either metabolized via the glycolytic pathway or stored as glycogen), activation of AMPK via this mutation has the potential to direct exogenous glucose away from glycolysis in favor of glycogen synthesis. Indeed, there was more than a 2-fold increase in both glycogen synthesis rates and total glycogen content in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit ( Figure 2C and 2D ). These findings are consistent with previous studies showing that subunit mutations result in glycogen accumulation both in the skeletal muscle and the heart (2, 18, 35). While the increase in glycogen levels in our model is modest compared to transgenic mice expressing 2 mutations (up to 30-fold more glycogen than controls), we are comparing only 48 hours of expression to the lifetime of the transgenic animal (3). However, the advantage of our model is that we can directly assess the effect of the mutation on AMPK activity and the functional consequences of this activation in the absence of (3, 40) .
While the dramatic depression in glycolytic rates may be one mechanism by which these mutations promote further glycogen accumulation, we also demonstrate that there was a significant increase in glycogen synthase activity, a reduction in inhibitory phosphorylation of glycogen synthase, and elevated glycogen synthase protein and mRNA expression ( Figure 3A-C) . Furthermore, GSK-3 protein and mRNA levels were both decreased by more than 50% in cells expressing the 1 R70Q mutation compared to the wildtype 1 subunit ( Figure 4A-B) . This effect appears to be specific to the mutated subunit as pharmacological activation of AMPK has no effect on GSK-3 protein level and may, in fact, result in activation of GSK-3 (11, 14, 25) . Therefore, the increase in glycogen synthase activity observed with expression of the AMPK 1 R70Q mutation was likely due to a combination of upregulation of glycogen synthase itself and reduced inhibition via GSK-3 .
Interestingly, the finding that GSK-3 protein levels were decreased with the expression of the 1 R70Q mutation also suggests that this mutation can modify pathways involved in regulating cardiac hypertrophic growth (1, 21) . Consistent with this, we show that depressed GSK-3 activity induced by expression of the 1 R70Q mutation increases nuclear NFAT activity ( Figure 4C ), which is a prerequisite for NFAT activation of the hypertrophic gene program (reviewed in (15)). Again, it appears that this effect is not a result of simple activation of AMPK, as AICAR induced a significant decrease in NFAT transcriptional activity (data not shown), consistent with prior studies indicating that AMPK is a negative regulator of hypertrophy (9, 29). While there was no observed hypertrophic growth associated with 48 hours of 1 R70Q mutant expression, protein synthesis trended to increase, and this mutation may induce a more subtle stimulation of the hypertrophic program that may not be as easily observed as with other inducers of hypertrophy such as phenylephrine.. Therefore with longer expression of the mutation, Based on the results of this study, expression of the AMPK-activating 1 R70Q mutation results in a re-routing of exogenous glucose toward glycogen synthesis as well as an activation of the ratelimiting enzyme glycogen synthase, leading to glycogen accumulation in neonatal rat cardiac myocytes.
In addition, cells expressing the mutated isoform have increased nuclear activity of the pro-hypertrophic transcription factor NFAT (summarized in Figure 5 ). Many of the effects induced by the 1 R70Q mutation occurred at the transcriptional level, indicating long-term changes. Since GSK-3 is an important negative regulator of both glycogen synthesis and hypertrophy, a long-term reduction in GSK-3 content of the magnitude observed upon expression of an 1 R70Q mutation could lead to excessive glycogen accumulation and hypertrophy, both of which are hallmarks of the cardiomyopathy associated with mutations in the 2 subunit of AMPK. As AMPK is known to interact with various transcription factors and transcriptional co-activators (reviewed in (28)), it is probable that the mutation either alters AMPK substrate specificity or subcellular localization, thereby promoting increased or inappropriate interaction with transcription factor(s)/co-activator(s) that control glycogen-related genes. Whether our findings using the 1 R70Q mutation define the precise mechanisms responsible for the cardiomyopathy observed in humans and mice expressing the 2 mutations is currently unknown. Indeed, a recent study using the 2 N488I transgenic mice also showed reduced flux of exogenous glucose through glycolysis and increased glycogen synthase activity and protein expression at 7 weeks (32). However, in contrast to our model system, they observed an increase in glycogen synthase phosphorylation. While we cannot 15 provide evidence to explain this difference, it is likely due to the differences in the effects of the two mutants of the subunit of AMPK and/or the differences in experimental models. In addition, our study shows a striking downregulation of GSK-3 , which relieves inhibition of glycogen synthase, leading to glycogen accumulation, while Luptak et al defined a pathway in which increased expression and activity of UDP-linked glucose pyrophosphorylase (UDPG-PPL) facilitated the observed increase in glycogen content (32) . Whether UDPG-PPL plays a role in our model system was not investigated.
While there have been no discoveries of human mutations in the AMPK 1 subunit, this may be due to the fact that 1 is ubiquitously expressed in all tissues and a mutation inducing effects of the magnitude seen in this study, especially during development may not be compatible with life. However this possibility has yet to be examined. Nevertheless, in addition to increased glucose uptake and UDPG-PPL activity defined in a recent publication (32), our study provides important new information as to the mechanisms by which a mutation in the subunit of AMPK causes altered AMPK signaling. In addition, this study has identified multiple pathways involved in regulating both cardiac myocyte metabolism and growth that are influenced by mutations in the subunits of AMPK and which may contribute to the development of the mutant-associated cardiomyopathy in humans. 
